Mode
Text Size
Log in / Sign up

Oncology

601 published articles · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Narrative review examines ulcerative colitis and colorectal cancer risk
Oncology Sys. Review
Narrative review examines ulcerative colitis and colorectal cancer risk Review of ulcerative colitis and colorectal cancer links in patients
This narrative review synthesizes evidence on ulcerative colitis and colorectal cancer risk. It discusses factors influencing this associati…
Ulcerative colitis patients face cancer risk driven by inflammation, but better disease control and modern treatments are lowering overall c…
Narrative review discusses high-throughput screening technologies for adoptive T cell therapy optimization
Oncology Sys. Review
Narrative review discusses high-throughput screening technologies for adoptive T cell therapy optimization Review of high-throughput screening technologies for adoptive T cell therapy optimization
This narrative review examines high-throughput screening technologies used to optimize adoptive T cell therapy (ACT). The authors synthesize…
High-throughput screening tools help overcome resistance in adoptive T cell therapy by identifying key targets and substances to boost cance…
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer
Oncology Phase II
Tucidinostat plus capecitabine shows 25.8% response in advanced HR-positive HER2-negative breast cancer New Drug Combo Helps Breast Cancer After CDK4/6 Failure
This phase 2 trial evaluated tucidinostat plus metronomic capecitabine with endocrine therapy in 66 patients with HR-positive HER2-negative …
A new drug mix shrinks tumors in advanced breast cancer patients whose disease grew after standard treatments failed.
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease.
Oncology Phase II
Talquetamab and teclistamab combination shows 79% response in relapsed multiple myeloma with extramedullary disease. Study looks at two antibody drugs for high-risk multiple myeloma
This phase 2 single-arm study evaluated a talquetamab and teclistamab combination in a high-risk population with relapsed/refractory multipl…
A new drug combo for high-risk multiple myeloma helped 79% of patients respond, but 31% faced serious infections and five treatment-related …
Meta-analysis reports high pooled complete response with ALA/MAL photodynamic therapy for superficial BCC
Oncology Meta-analysis
Meta-analysis reports high pooled complete response with ALA/MAL photodynamic therapy for superficial BCC Light vs. Scalpel: New Skin Cancer Data
This PRISMA 2020 systematic review and meta-analysis of 55 studies (2123 patients, 2995 lesions) evaluated ALA-PDT and MAL-PDT for superfici…
Light therapy with cream may match surgery for treating common skin cancer while avoiding scars and functional damage to your face or neck.
Case report details endoscopic resection for sphenoid sinus myofibroma in a 60-year-old woman
Oncology Sys. Review
Case report details endoscopic resection for sphenoid sinus myofibroma in a 60-year-old woman Surgery for rare sphenoid sinus myofibroma in one patient showed no complications
This case report with narrative review describes endoscopic endonasal transsphenoidal resection in a 60-year-old female patient with sphenoi…
Endoscopic surgery successfully removed a rare skull base tumor in a 60-year-old woman, restoring her vision and relieving her pain without …
High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP.
Oncology Cohort
High FGR protein expression associated with worse relapse-free survival in de novo DLBCL patients treated with R-CHOP. New Protein Test Predicts Lymphoma Relapse Risk
This retrospective cohort study evaluated 91 patients with de novo diffuse large B-cell lymphoma treated with R-CHOP. High FGR protein expre…
A new protein test identifies diffuse large B-cell lymphoma patients at high risk of relapse before treatment fails, giving doctors a crucia…
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab.
Oncology Cohort
Salvage radiotherapy for limited metastatic relapse in small cell lung cancer after durvalumab. Two patients with limited-stage small cell lung cancer had durable disease control after salvage radiotherapy and immunotherapy
This case report describes two patients with limited-stage small cell lung cancer who developed limited metastatic relapse after chemoradiot…
Two limited-stage small cell lung cancer patients stayed stable for over four years after targeted radiation and continued immunotherapy.
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis
Oncology Cohort
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis Local therapy linked to better survival in advanced breast cancer patients with specific metastases
This retrospective cohort study of 1110 patients across two tertiary centers compared outcomes in isolated contralateral axillary metastasis…
Patients with specific breast cancer spread to the opposite armpit survived longer when receiving surgery or radiation compared to systemic …
Multimodal CNN outperforms PSA alone for prostate cancer diagnosis in biopsy-confirmed patients
Oncology Cohort
Multimodal CNN outperforms PSA alone for prostate cancer diagnosis in biopsy-confirmed patients New MRI tool may improve prostate cancer diagnosis compared to PSA alone
This retrospective cohort study evaluated 305 patients with PSA levels 4–10 ng/mL who underwent multiparametric MRI and biopsy. A multimodal…
A new AI tool analyzing MRI scans correctly identified prostate cancer in 85.3% of cases and ruled it out in 90.9%, far outperforming PSA bl…
No primary data reported; publication type and scope are not specified in the provided input.
Oncology
No primary data reported; publication type and scope are not specified in the provided input. Mouth Bacteria May Guide Breast Cancer Screening
The provided input does not specify a publication type, study design, or scope. Consequently, no synthesized findings, effect sizes, or clin…
Tiny mouth bacteria might help doctors find breast cancer earlier by sending signals through your blood to warn of trouble.
FDA Approves Danziten (nilotinib) for Adult Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML
Oncology FDA Approval
FDA Approves Danziten (nilotinib) for Adult Patients with Newly Diagnosed or Resistant/Intolerant Ph+ CML The FDA approved a new drug called Danziten for a type of blood cancer called CML.
Danziten (nilotinib) is approved for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML)…
The FDA approved Danziten to treat newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia or cases resistant to prior ima…